SCHEMBL30765608

SCHEMBL30765608

CCCCOC(=O)Cn1c(-c2ccc(O[C@@H]3CO[C@H]4[C@@H]3OC[C@H]4O)cc2)ncc(NCCCc2ccccc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ELANE P08246 9/20 0.38
BCHE P06276 4/20 0.37
ADORA3 P0DMS8 2/20 0.36
ADORA2B P29275 2/20 0.36
AVPR1B P47901 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765638 0.93 GAA (0.41) GAAL3MBTL1ELANEBCHEADORA3
SCHEMBL30765687 0.90 BCHE (0.41) ELANEBCHEADORA3ADORA2BNPC1
SCHEMBL30765978 0.84 ELANE (0.41) ELANEBCHEADORA3ADORA2BNPC1
SCHEMBL30765463 0.84 GAA (0.44) GAAL3MBTL1ELANEADORA3ADORA2B
SCHEMBL30765476 0.83 ELANE (0.40) ELANEBCHEAVPR1BNPC1RAB9A
SCHEMBL30765613 0.83 GAA (0.50) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765744 0.83 BCHE (0.38) GAAL3MBTL1BCHEMEN1KMT2A
SCHEMBL30766052 0.82 KLK7 (0.42) ELANEBCHE
SCHEMBL30766150 0.81 GAA (0.52) GAAL3MBTL1ELANEAVPR1BMEN1
SCHEMBL30765630 0.80 GAA (0.47) GAAL3MBTL1ELANEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed